Clonazepam Tablet
NDC 72789-314
Product Information
Clonazepam is a ANDA-approved product labeled by Pd-rx Pharmaceuticals, Inc.. Clonazepam is used to prevent and control seizures. It is supplied as a blue tablet for oral administration. This product entry covers the primary NDC 72789-314 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
2531;V
Code Structure Chart
Product Details
What is NDC 72789-314?
What are the uses of this product?
What are Active Ingredients of this product?
- CLONAZEPAM 1 mg/1 - An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- CLONAZEPAM (UNII: 5PE9FDE8GB)
- CLONAZEPAM (UNII: 5PE9FDE8GB) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- SILICON DIOXIDE (UNII: ETJ7Z6XBU4)
- CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)
- LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)
- FD&C BLUE NO. 1 (UNII: H3R47K3TBD)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 197528 - clonazePAM 1 MG Oral Tablet
- RxCUI: 197528 - clonazepam 1 MG Oral Tablet
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.